Biological response of adrenal carcinoma and melanoma cells to mitotane treatment.
Ontology highlight
ABSTRACT: A previous case report described an adrenal incidentaloma initially misdiagnosed as adrenocortical carcinoma (ACC), which was treated with mitotane. The final diagnosis was metastatic melanoma of unknown primary origin. However, the patient developed rapid disease progression after mitotane withdrawal, suggesting a protective role for mitotane in a non-adrenal-derived tumor. The aim of the present study was to determine the biological response of primary melanoma cells obtained from that patient, and that of other established melanoma and ACC cell lines, to mitotane treatment using a proliferation assay, flow cytometry, quantitative PCR and microarrays. Although mitotane inhibited the proliferation of both ACC and melanoma cells, its role in melanoma treatment appears to be limited. Flow c
SUBMITTER: Stelcer E
PROVIDER: S-EPMC8855164 | biostudies-literature | 2022 Apr
REPOSITORIES: biostudies-literature
ACCESS DATA